Cargando…
Cardiovascular Health and Disease in the Context of COVID-19
First documented in China in early December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and continues to test the strength of healthcare systems and public health programs all over the world. Underlying cardiovascular disease has been recognized as a r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935632/ https://www.ncbi.nlm.nih.gov/pubmed/33738009 http://dx.doi.org/10.14740/cr1199 |
_version_ | 1783661040749248512 |
---|---|
author | Umbrajkar, Sidhant Stankowski, Rachel V. Rezkalla, Shereif Kloner, Robert A. |
author_facet | Umbrajkar, Sidhant Stankowski, Rachel V. Rezkalla, Shereif Kloner, Robert A. |
author_sort | Umbrajkar, Sidhant |
collection | PubMed |
description | First documented in China in early December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and continues to test the strength of healthcare systems and public health programs all over the world. Underlying cardiovascular disease has been recognized as a risk factor for coronavirus disease 2019 (COVID-19)-related morbidity and mortality since the early days of the pandemic. In addition, evidence demonstrates cardiac and endothelial damage in somewhere between one-third and three-quarters of individuals with COVID-19, regardless of symptom severity. This damage is thought to be mediated by direct viral infection, immunopathology and hypoxemia with the additional possibility of exacerbation via medication-induced cardiotoxicity. Clinically, the cardiovascular consequences of COVID-19 may present as myocarditis with or without arrhythmia, endothelial dysfunction and thrombosis, acute coronary syndromes and heart failure. Presentation can vary widely and may or may not be typical of the condition in an individual without COVID-19. There is evidence to support the prognostic utility of cardiac biomarkers (e.g., cardiac troponin) and imaging studies (e.g., echocardiography, cardiac magnetic resonance imaging) in the context of COVID-19 and building evidence suggests that cardiovascular screening may be warranted even among those with asymptomatic or mild infection and those without traditional cardiovascular risk factors. In addition, evidence suggests the potential for long-term cardiovascular consequences for those who recover from COVID-19 with implications for the field of cardiology long into the future. Even among those without COVID-19, disruption of infrastructure and changes in human behavior as a result of the pandemic also have an upstream role in cardiovascular outcomes, which have already been documented in multiple locations. This review summarizes what is currently known regarding the pathogenic mechanisms of COVID-19-related cardiovascular injury and describes clinical cardiovascular presentations, prognostic indicators, recommendations for screening and treatment, and long-term cardiovascular consequences of infection. Ultimately, medical personnel must be vigilant in their attention to possible cardiovascular symptoms, take appropriate steps for clinical diagnosis and be prepared for long-term ramifications of myocardial injury sustained as a result of COVID-19. |
format | Online Article Text |
id | pubmed-7935632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79356322021-03-17 Cardiovascular Health and Disease in the Context of COVID-19 Umbrajkar, Sidhant Stankowski, Rachel V. Rezkalla, Shereif Kloner, Robert A. Cardiol Res Review First documented in China in early December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and continues to test the strength of healthcare systems and public health programs all over the world. Underlying cardiovascular disease has been recognized as a risk factor for coronavirus disease 2019 (COVID-19)-related morbidity and mortality since the early days of the pandemic. In addition, evidence demonstrates cardiac and endothelial damage in somewhere between one-third and three-quarters of individuals with COVID-19, regardless of symptom severity. This damage is thought to be mediated by direct viral infection, immunopathology and hypoxemia with the additional possibility of exacerbation via medication-induced cardiotoxicity. Clinically, the cardiovascular consequences of COVID-19 may present as myocarditis with or without arrhythmia, endothelial dysfunction and thrombosis, acute coronary syndromes and heart failure. Presentation can vary widely and may or may not be typical of the condition in an individual without COVID-19. There is evidence to support the prognostic utility of cardiac biomarkers (e.g., cardiac troponin) and imaging studies (e.g., echocardiography, cardiac magnetic resonance imaging) in the context of COVID-19 and building evidence suggests that cardiovascular screening may be warranted even among those with asymptomatic or mild infection and those without traditional cardiovascular risk factors. In addition, evidence suggests the potential for long-term cardiovascular consequences for those who recover from COVID-19 with implications for the field of cardiology long into the future. Even among those without COVID-19, disruption of infrastructure and changes in human behavior as a result of the pandemic also have an upstream role in cardiovascular outcomes, which have already been documented in multiple locations. This review summarizes what is currently known regarding the pathogenic mechanisms of COVID-19-related cardiovascular injury and describes clinical cardiovascular presentations, prognostic indicators, recommendations for screening and treatment, and long-term cardiovascular consequences of infection. Ultimately, medical personnel must be vigilant in their attention to possible cardiovascular symptoms, take appropriate steps for clinical diagnosis and be prepared for long-term ramifications of myocardial injury sustained as a result of COVID-19. Elmer Press 2021-04 2021-02-23 /pmc/articles/PMC7935632/ /pubmed/33738009 http://dx.doi.org/10.14740/cr1199 Text en Copyright 2021, Umbrajkar et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Umbrajkar, Sidhant Stankowski, Rachel V. Rezkalla, Shereif Kloner, Robert A. Cardiovascular Health and Disease in the Context of COVID-19 |
title | Cardiovascular Health and Disease in the Context of COVID-19 |
title_full | Cardiovascular Health and Disease in the Context of COVID-19 |
title_fullStr | Cardiovascular Health and Disease in the Context of COVID-19 |
title_full_unstemmed | Cardiovascular Health and Disease in the Context of COVID-19 |
title_short | Cardiovascular Health and Disease in the Context of COVID-19 |
title_sort | cardiovascular health and disease in the context of covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935632/ https://www.ncbi.nlm.nih.gov/pubmed/33738009 http://dx.doi.org/10.14740/cr1199 |
work_keys_str_mv | AT umbrajkarsidhant cardiovascularhealthanddiseaseinthecontextofcovid19 AT stankowskirachelv cardiovascularhealthanddiseaseinthecontextofcovid19 AT rezkallashereif cardiovascularhealthanddiseaseinthecontextofcovid19 AT klonerroberta cardiovascularhealthanddiseaseinthecontextofcovid19 |